Literature DB >> 27792249

A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology.

Ryusuke Hatae1, Nobuhiro Hata1, Satoshi O Suzuki2, Koji Yoshimoto1, Daisuke Kuga1, Hideki Murata1, Yojiro Akagi1, Yuhei Sangatsuda1, Toru Iwaki2, Masahiro Mizoguchi3, Koji Iihara1.   

Abstract

Brain tumors harbor various BRAF alterations, the vast majority of which are the BRAF kinase-activating V600E mutation. BRAF mutations are most frequently detected in certain subtypes of low-grade glioma, such as pilocytic astrocytoma (PA), pleomorphic xanthoastrocytoma (PXA), ganglioglioma (GG) and dysembryoplastic neuroepithelial tumor (DNT). However, it is unclear whether gliomas harboring BRAF mutations can be invariably regarded as these glioma subtypes or their derivatives. To address this question, we analyzed 274 gliomas in our institutional case series. We performed high-resolution melting analyses and subsequent direct Sanger sequencing on DNA isolated from snap-frozen tumor tissues. As expected, BRAF mutations were detected in the aforementioned low-grade gliomas: in 4/27 PAs, 2/3 PXAs, 4/8 GGs, and 1/6 DNTs. In addition to these gliomas, 1/2 astroblastomas (ABs) and 2/122 glioblastomas (GBs) harbored BRAF mutations. Pathological investigation of the two GBs revealed that one was a GB displaying epithelial features that presumably arose from a precedent GG, whereas the other GB, which harbored a rare G596 A mutation, showed marked epithelial features, including astroblastic rosettes. Our results indicate that in addition to being present in established BRAF-associated gliomas, BRAF mutations might be associated with epithelial features in high-grade gliomas, including sheet-like arrangement of polygonal tumor cells with a plump cytoplasm and astroblastic rosettes, and thus could potentially serve as a genetic marker for these features.
© 2016 Japanese Society of Neuropathology.

Entities:  

Keywords:  BRAF; G596 A; astroblastic rosette; glioblastoma; glioma

Mesh:

Substances:

Year:  2016        PMID: 27792249     DOI: 10.1111/neup.12347

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  5 in total

1.  Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study.

Authors:  Elke Pfaff; Tobias Kessler; Gnana Prakash Balasubramanian; Anne Berberich; Daniel Schrimpf; Antje Wick; Jürgen Debus; Andreas Unterberg; Martin Bendszus; Christel Herold-Mende; David Capper; Irini Schenkel; Andreas Eisenmenger; Susan Dettmer; Benedikt Brors; Michael Platten; Stefan M Pfister; Andreas von Deimling; David T W Jones; Wolfgang Wick; Felix Sahm
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

2.  Clinical implications of molecular analysis in diffuse glioma stratification.

Authors:  Masahiro Mizoguchi; Nobuhiro Hata; Daisuke Kuga; Ryusuke Hatae; Yojiro Akagi; Yuhei Sangatsuda; Yutaka Fujioka; Kosuke Takigawa; Yusuke Funakoshi; Satoshi O Suzuki; Toru Iwaki
Journal:  Brain Tumor Pathol       Date:  2021-07-15       Impact factor: 3.298

Review 3.  BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors.

Authors:  Karisa C Schreck; Stuart A Grossman; Christine A Pratilas
Journal:  Cancers (Basel)       Date:  2019-08-28       Impact factor: 6.639

4.  Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.

Authors:  Alan Mackay; Anna Burford; Valeria Molinari; David T W Jones; Elisa Izquierdo; Jurriaan Brouwer-Visser; Felice Giangaspero; Christine Haberler; Torsten Pietsch; Thomas S Jacques; Dominique Figarella-Branger; Daniel Rodriguez; Paul S Morgan; Pichai Raman; Angela J Waanders; Adam C Resnick; Maura Massimino; Maria Luisa Garrè; Helen Smith; David Capper; Stefan M Pfister; Thomas Würdinger; Rachel Tam; Josep Garcia; Meghna Das Thakur; Gilles Vassal; Jacques Grill; Tim Jaspan; Pascale Varlet; Chris Jones
Journal:  Cancer Cell       Date:  2018-05-14       Impact factor: 31.743

5.  Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma.

Authors:  Kosuke Takigawa; Nobuhiro Hata; Yuhei Michiwaki; Akio Hiwatashi; Hajime Yonezawa; Daisuke Kuga; Ryusuke Hatae; Yuhei Sangatsuda; Yutaka Fujioka; Yusuke Funakoshi; Ryosuke Otsuji; Aki Sako; Osamu Togao; Takashi Yoshiura; Koji Yoshimoto; Masahiro Mizoguchi
Journal:  J Neurooncol       Date:  2021-07-28       Impact factor: 4.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.